Setmelanotide

Setmelanotide is a peptide drug that activates the melanocortin-4 receptor (MC4R), a key switch in the brain's appetite control center Hypothalamic obesity. Unlike common weight-loss drugs, it was developed specifically for rare forms of severe obesity where the body's natural "fullness" signal – the leptin-melanocortin pathway – is broken because of a genetic defect or damage to the hypothalamus Hypothalamic obesity+1.

It is approved for use in certain genetic obesity syndromes, including Bardet-Biedl syndrome and deficiencies in LEPR, POMC, or PCSK1. In these conditions, setmelanotide can dramatically reduce the intense, uncontrollable hunger (hyperphagia) that drives weight gain Hypothalamic obesity+1. Research is also exploring its benefit in acquired hypothalamic obesity – a type of obesity that follows brain tumors, surgery, or radiation Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.

Setmelanotide works by mimicking the action of melanocortin hormones in the brain. These hormones normally activate MC4 receptors in the hypothalamus, telling the body to reduce appetite and increase energy use Hypothalamic obesity. In many rare genetic obesities, the chain of signals that leads to MC4R activation is broken. Because setmelanotide acts directly on the MC4 receptor, it can bypass those upstream defects and restore the “stop eating” signal Hypothalamic obesity+1.

The drug’s effect isn’t just about meal-to-meal hunger. Research shows it also influences longer-term energy balance pathways, including AMPK signaling and interactions with β-arrestin-2, which may explain why it can improve body weight and metabolic health over months Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort+1. Additionally, MC4 receptors are found in brain circuits that control breathing and stress responses, hinting at broader effects on ventilation and behavior Melanocortin-4 Receptor Agonist Treatment of Hypothalamic Obesity in ROHHAD Syndrome+1.

Weight and Appetite Control

In people with specific MC4R pathway deficiencies, setmelanotide has been shown to significantly lower body weight and reduce hyperphagia. For example, in Bardet-Biedl syndrome, a 52-week study found that 58.6% of those on setmelanotide achieved a meaningful weight response, compared to only 6.9% in a matched untreated group Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. In a 2-year-old child with LEPR deficiency, BMI and food-seeking behaviors improved over nearly two years of daily treatment Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial.

Metabolic Health Improvements

Beyond weight, research has noted improvements in fatty liver disease (MASLD), blood sugar control, and kidney function in people with Bardet-Biedl syndrome. One real-world study reported resolution or stabilization of liver steatosis in 85% of patients after 6 months Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome. Some patients also had better HbA1c and estimated kidney filtration rates Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.

Side Effect Profile

The most notable side effect is skin darkening (hyperpigmentation), which occurs in many users due to melanocortin receptor activation on skin cells Drug induced hyperpigmentation: systematic review and meta-analysis. Other reported effects include injection-site reactions, spontaneous erections at high doses, and rare rash Melanocortin-4 Receptor Agonist Treatment of Hypothalamic Obesity in ROHHAD Syndrome+1. Dermatology monitoring is advised, especially for people with many moles Drug induced hyperpigmentation: systematic review and meta-analysis.

Research protocols for setmelanotide always use subcutaneous injection, once daily Hypothalamic obesity+1. The dose is started low and increased gradually to balance appetite suppression with tolerability. In adults, a common starting dose is 1 mg per day, titrated up every 1–2 weeks to a target of 2–3 mg per day. In severe hypothalamic obesity, some protocols have escalated to 5 mg daily Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.

The goal is sustained hyperphagia control and steady weight reduction over months, not rapid loss. Treatment is typically continuous; planned breaks are rare and can lead to rapid regain of appetite and weight Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. In very young children, starting doses as low as 0.5 mg have been used, with careful titration in small steps Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial.

Timing of injection does not appear critical, but morning dosing is often preferred to align with daytime hunger patterns and to make side-effect monitoring easier (community consensus).

Setmelanotide must be reconstituted from a lyophilized powder before subcutaneous injection. Bacteriostatic water is the standard diluent, as it helps keep the solution sterile during multi-dose use (community consensus). After adding the appropriate amount of diluent, gently swirl the vial to dissolve the powder – do not shake. Once mixed, store the vial in the refrigerator (2–8°C) and protect it from light (community consensus).

Unreconstituted powder can be kept in the freezer for long-term storage, or refrigerated for shorter periods. Once reconstituted, the solution is generally stable for up to 30 days with bacteriostatic water, provided it remains clear and free of particles. Never freeze a reconstituted vial (community consensus).

For detailed dosing volumes based on your vial size and prescribed dose, use the interactive calculator below.

Drug Interactions

Setmelanotide’s unique mechanism means it does not directly interfere with most common medications through the liver’s enzyme system. However, combining it with other appetite-reducing drugs like semaglutide or tirzepatide could amplify weight loss and side effects, so careful titration is needed Hypothalamic obesity+1. Sympathomimetics (e.g., phentermine) may increase heart rate and anxiety when used together. Antipsychotics that promote weight gain may partially counteract setmelanotide’s effects.

No significant interactions with blood pressure, diabetes, or steroid medications are known, but patients using insulin or sulfonylureas should watch for low blood sugar as weight drops.

Supplement Considerations

Stimulant supplements (caffeine, yohimbine) may compound side effects like palpitations. Glucose-lowering supplements (berberine, chromium) could, in theory, increase hypoglycemia risk when combined with diabetic medications. No documented interactions with common vitamins or herbal sleep aids exist, though sedating supplements should be used cautiously in those with breathing problems.

Unlike many research peptides, setmelanotide is not used in short “on/off” cycles. The evidence supports continuous daily use for months to years, with benefits accumulating over time. Stopping treatment can quickly reverse its appetite-suppressing and weight-loss effects Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.

Some people do take short breaks (1–2 weeks) to manage persistent side effects like hyperpigmentation or spontaneous erections, or to see if the drug is still working. If you are off for more than a few weeks, it’s best to restart at a low dose and titrate back up (community consensus). No evidence suggests that planned cycling improves long-term response.

Research into stacking setmelanotide with other peptides is limited, but some combinations are plausible. Because setmelanotide targets the brain’s MC4 receptor while GLP-1 agonists like semaglutide work through gut hormone pathways, they may work together for greater appetite suppression. Case reports in hypothalamic obesity show tirzepatide can provide additional weight loss, but formal combination studies are lacking.

Avoid stacking with other melanocortin agonists (e.g., melanotan II, PT-141), as this could overstimulate the same pathway and increase side effects like hyperpigmentation without proven benefit. Peptides that increase hunger (like some growth hormone secretagogues) would work against setmelanotide’s purpose and are generally not combined.

Setmelanotide (brand name Imcivree) is FDA-approved in the United States for several rare genetic obesity disorders, including Bardet-Biedl syndrome and deficiencies in POMC, PCSK1, and LEPR Hypothalamic obesity+1. Research is also exploring its use in acquired hypothalamic obesity, though it is not yet FDA-approved for this indication Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. It is available only by prescription and is not approved for common obesity.

Internationally, regulatory bodies like Health Canada have recommended coverage under specific conditions, and orphan-drug designations have been granted in Europe Setmelanotide (Imcivree). The drug is not a controlled substance. For athletes, setmelanotide is not listed on WADA’s prohibited list, but athletes should check with their sport’s governing body regarding therapeutic use exemptions.

The most common side effect of setmelanotide is skin darkening (hyperpigmentation), which occurs because MC4 receptors are also present in skin cells Drug induced hyperpigmentation: systematic review and meta-analysis. This change can be widespread and may be permanent to some degree. Other reported effects include injection-site reactions, nausea, and spontaneous erections – the latter especially at higher doses Melanocortin-4 Receptor Agonist Treatment of Hypothalamic Obesity in ROHHAD Syndrome+1.

Serious risks appear low, but dermatology check-ups are recommended to monitor any new or changing moles, as melanocyte activity can increase Drug induced hyperpigmentation: systematic review and meta-analysis. No safety data exist for pregnancy or breastfeeding, and caution is advised in those with severe liver or kidney disease. Blood pressure and heart rate should be followed during dose escalation, as MC4R activation can influence autonomic functions.